Exagen (XGN) Cash & Equivalents (2018 - 2026)

Exagen (XGN) has 9 years of Cash & Equivalents data on file, last reported at $21.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 92.18% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (up 92.18% YoY) and the FY2025 annual result came in at $32.2 million, up 46.22% from the prior year.
• Cash & Equivalents eased to $21.5 million in Q1 2026, from $32.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $89.8 million in Q1 2022 to a low of $11.2 million in Q1 2025.
• A 5-year average of $39.5 million and a median of $31.5 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 58.95% — and 2026, when it jumped 92.18%.
• Tracing XGN's Cash & Equivalents over 5 years: stood at $62.4 million in 2022, then tumbled by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then soared by 46.22% to $32.2 million in 2025, then plunged by 33.23% to $21.5 million in 2026.
• The last three Cash & Equivalents figures came in at $21.5 million (Q1 2026), $32.2 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.